Ann: ResMed Announces Results for the Fourth Quarter of FY2023, page-195

I see a few posts that don't quite hit the mark with this debate. So I thought I'd try and help clarify things a bit more.

GLP1's are not new, the understanding of the effect on Obesity and OSA is not new. Eli Lilly's drug is however new, but it's mechanism of action is the same as the others. Below is the link to their study.

https://classic.clinicaltrials.gov/ct2/show/NCT05412004

"The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP) therapy in GPI1 and those who are and plan to stay on PAP therapy in GPI2." It's a trial which is measuring the effect of giving Trizepatide to those who have BOTH sleep Apnea and are obese. Which is a big difference to "Anyone with sleep Apnea"

The first group of the study is those who ARE NOT on PAP therapy.
The second group of the study is those who ARE on PAP therapy.

What they will be hoping to show, is that those who are obese can show a reduction in AHI (Sleep Apnea symptoms) by using the drug. The change will be measured in group 1 and 2 (This has already been proven by previous studies).

There are a quite a few notable exclusions for participants.



So in answer to the questions in this thead, it's not that this drug does anything different form other GLP1's. It's just that Eli Lilly have decided they want to test specifically for whether their drug can reduce AHI in obese persons. A reduction in obesity has already been shown to reduce OSA in up to 50% of obese patients.

This isn't to say it actually prevents it or cures it completely. The reduction from baseline may only be say 40%, which would be statistically significant but may not be necessarily be enough for long term effective treatment of Sleep Apnea when compared to a CPAP device or in combination.

Other studies have already been done on this, so I would reiterate it's not new. They have a host of side effects, are expensive a nobody likes injecting all the time.


They are currently prescribed as part of the treatment plan.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410036/






I would also argue that trust in Pharma is getting worse not better. Additionally, Eli Lily's study is not a long term trial, so it doesn't do anything to solve the existing concerns.